Roche's (RHHBY) Genentech Gets Extended FDA Approval for Tamiflu

December 21, 2012 1:45 PM EST Send to a Friend
Get Alerts RHHBY Hot Sheet
Trade RHHBY Now!
Join SI Premium – FREE
Genentech, a member of the Roche Group (OTCBB: RHHBY), announced that the U.S. Food and Drug Administration (FDA) has extended the approval of Tamiflu (oseltamivir phosphate) for the treatment of acute, uncomplicated influenza to include infants two weeks of age and older.i Tamiflu is prescribed by doctors to help lessen the duration and severity of influenza by blocking the virus’ ability to replicate in the body.

The approval makes Tamiflu the only prescription oral antiviral medicine approved to treat people of all ages, from infants two weeks of age to elderly people. Tamiflu was first approved in the United States over 13 years ago.i Approximately 30 million children worldwide over the age of one, including an estimated 6.9 million children in the United States, have received a prescription for Tamiflu.ii


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA

Add Your Comment